PASG Stock Summary and Trading Ideas (Passage Bio | NASDAQ:PASG)

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Passage Bio trades on the NASDAQ stock market under the symbol PASG.

As of July 23, 2026, PASG stock price declined to $4.90 with 2,089 million shares trading.

PASG has a beta of 3.88, meaning it tends to be more sensitive to market movements. PASG has a correlation of 0.12 to the broad based SPY ETF.

PASG has a market cap of $15.74 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PASG traded as high as $35.80 and as low as $3.29.

The top ETF exchange traded funds that PASG belongs to (by Net Assets): VTI, VXF, DFAC.

PASG has underperformed the market in the last year with a return of -13.6%, while the SPY ETF gained +18.6%. In the last 3 month period, PASG fell short of the market, returning -20.1%, while SPY returned +4.1%. However, in the most recent 2 weeks PASG has outperformed the stock market by returning +1.7%, while SPY returned -1.0%.

PASG support price is $4.61 and resistance is $5.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PASG shares will trade within this expected range on the day.